Audrey Thomas-Schoemann, PharmD, PhD

The purpose of this observational study is to evaluate the benefits of a pharmacist integration in an oncology ambulatory center, to prevent drug related problems (in particular drug drug interactions) at antitumor treatment initiation.

The hypothesis of this work is that a drug drug interaction will be observed in 30% of cancer patients and will have a major clinical impact in 1% of the cases. The primary endpoint is the prevalence of pharmacist interventions among patients who are going to receive an oral targeted therapy or cancer chemotherapy or immunotherapy

The purpose of this observational study is to evaluate the benefits of a pharmacist integration in an oncology ambulatory center, to prevent drug related problems (in particular drug drug interactions) at antitumor treatment initiation.

The hypothesis of this work is that a drug drug interaction will be observed in 30% of cancer patients and will have a major clinical impact in 1% of the cases.

The primary endpoint is the prevalence of pharmacist interventions among cancer patients who are going to receive an oral targeted therapy (140 patients) or cancer chemotherapy or immunotherapy (300 patients).

Pharmacist interventions will be classified according to the SFPC (société française de pharmacie Clinique) classification.

The secondary endpoints are

* The detection of drug drug interactions with theriaque software, Micromedex software and DDI predictor tool.
* The clinical gradation by an independent expert comity of the clinical impact of avoided drug drug interaction. The expert comity will grade avoided clinical consequences in 3 levels (minor, moderate or major),
* The Economic evaluation of pharmacist intervention: Cost of the project to evaluate drug drug interaction and benefits after evaluation of avoided clinical consequences
* The Adherence evaluation of patients treated with oral cancer targeted therapy (Therefore, only patients under oral targeted therapy will be evaluated at Day0, Day15 ,Day 30 and Month 6 to determine adherence.)

Role of the Pharmacist in Detection of Drug Interactions Before Antitumor Treatment Initiation

Role of the Clinical Pharmacist in an Oncology Ambulatory Center to Prevent Drug Related Problems Before Antitumor Treatment Initiation

Percentage of patients whom antitumora treatment or usual treatment has been changed by the pharmacist intervention

Number of drug drug interactions detected

Gradation by an independent experts comity of the clinical impact of prevented drug drug interaction

Cost evaluation of pharmacist for analysis and medication review with patient by avoided interaction

Treatment cost of avoided clinical consequences , balanced with the probability of occurrence

Patients with plasma drug concentration below the 10th percentile will be classified as nonadherent patients

Patients with a Girerd score greater than or equal to 3 will be classified as nonadherent patients

Pill counts will be used to calculate the percent of total prescribed dose taken to prescribed during the 90-day period

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Role of the Pharmacist in Detection of Drug Interactions Before Antitumor Treatment Initiation	NCT04142567	Neoplasm		18 Years -	Assistance Publique - Hôpitaux de Paris
Role of the Pharmacist in Detection of Drug Interactions Before Antitumor Treatment Initiation	NCT04142567	Neoplasm		18 Years -	Assistance Publique - Hôpitaux de Paris

Spots Global Cancer Trial Database for pharmacist interventions